Free Trial
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Marinus Pharmaceuticals logo
$0.55 0.00 (-0.16%)
As of 02/11/2025

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Key Stats

Today's Range
$0.55
$0.55
50-Day Range
$0.55
$0.55
52-Week Range
$0.22
$1.97
Volume
260 shs
Average Volume
1.82 million shs
Market Capitalization
$30.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.92
Consensus Rating
Hold

Company Overview

Marinus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

MRNS MarketRank™: 

Marinus Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 636th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Marinus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Marinus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marinus Pharmaceuticals has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Marinus Pharmaceuticals' valuation and earnings.
  • Short Interest

    There is no current short interest data available for MRNS.
  • Dividend Yield

    Marinus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Marinus Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MRNS.
  • MarketBeat Follows

    2 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Marinus Pharmaceuticals' insider trading history.
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Marinus (MRNS) Gets a Hold from Truist Financial
See More Headlines

MRNS Stock Analysis - Frequently Asked Questions

Marinus Pharmaceuticals' stock was trading at $0.5351 at the start of the year. Since then, MRNS stock has increased by 2.6% and is now trading at $0.5491.
View the best growth stocks for 2025 here
.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.01. The biopharmaceutical company had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 7,831.35% and a negative net margin of 446.48%.
Read the conference call transcript
.

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020.The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/13/2024
Today
7/02/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRNS
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.92
High Stock Price Target
$10.00
Low Stock Price Target
$0.50
Potential Upside/Downside
+613.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.40 million
Net Margins
-446.48%
Pretax Margin
-446.48%

Debt

Sales & Book Value

Annual Sales
$30.99 million
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
1.77

Miscellaneous

Free Float
52,203,000
Market Cap
$30.32 million
Optionable
Optionable
Beta
1.03

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MRNS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners